Nahla Khawaja1, Hala Owaineh1, Anwar Batieha2, Oraib Frahid1, Mohammed El-Khateeb1, Kamel M Ajlouni3. 1. The National Center (Institute) for Diabetes, Endocrinology and Genetics, University of Jordan, Amman, Jordan. 2. Department of Community Medicine, Jordan University of Science and Technology, Irbid, Jordan. 3. The National Center (Institute) for Diabetes, Endocrinology and Genetics, University of Jordan, Amman, Jordan, ajlouni@ju.edu.jo.
Abstract
OBJECTIVE: To assess final adult height (FAH) in children with short stature treated with gonadotropin-releasing hormone analogue (GnRHa). METHODS: All patients with idiopathic short stature (ISS) with normally timed puberty and a Tanner stage between 2 and 3, who achieved their FAH between 2005 and 2015, were included in this clinical historical cohort study. Height gain, FAH, and mid-parental height of 28 children with ISS who received GnRHa treatment for 1.8 ± 1.0 years to delay their puberty were compared to 31 untreated children. RESULTS: The FAHs of the treated and the untreated girls were 151.3 ± 5.1 and 146.8 ± 3.8 cm (p = 0.01), respectively. The FAHs of the treated and the untreated boys were 156.4 ± 4.7 and 152.3 ± 5.7 cm (p = 0.111), respectively. The height gain in the treated and the untreated girls was 1.6 ± 7.8 and -3.6 ± 5.7 cm (p = 0.036), respectively. Height gain in the treated and the untreated boys was -5.1 ± 13.6 and -11.5 ± 8.4 cm (p = 0.171), respectively. CONCLUSION: GnRHa therapy has a modest effect in improving FAH in adolescent females with ISS but not in boys.
OBJECTIVE: To assess final adult height (FAH) in children with short stature treated with gonadotropin-releasing hormone analogue (GnRHa). METHODS: All patients with idiopathic short stature (ISS) with normally timed puberty and a Tanner stage between 2 and 3, who achieved their FAH between 2005 and 2015, were included in this clinical historical cohort study. Height gain, FAH, and mid-parental height of 28 children with ISS who received GnRHa treatment for 1.8 ± 1.0 years to delay their puberty were compared to 31 untreated children. RESULTS: The FAHs of the treated and the untreated girls were 151.3 ± 5.1 and 146.8 ± 3.8 cm (p = 0.01), respectively. The FAHs of the treated and the untreated boys were 156.4 ± 4.7 and 152.3 ± 5.7 cm (p = 0.111), respectively. The height gain in the treated and the untreated girls was 1.6 ± 7.8 and -3.6 ± 5.7 cm (p = 0.036), respectively. Height gain in the treated and the untreated boys was -5.1 ± 13.6 and -11.5 ± 8.4 cm (p = 0.171), respectively. CONCLUSION: GnRHa therapy has a modest effect in improving FAH in adolescent females with ISS but not in boys.
Authors: M Tauber; B Berro; V Delagnes; N Lounis; B Jouret; C Pienkowski; I Oliver; P Rochiccioli Journal: J Clin Endocrinol Metab Date: 2003-03 Impact factor: 5.958
Authors: Jack A Yanovski; Susan R Rose; Giovanna Municchi; Ora H Pescovitz; Suvimol C Hill; Fernando G Cassorla; Gordon B Cutler Journal: N Engl J Med Date: 2003-03-06 Impact factor: 91.245
Authors: Gillian M Maher; Lisa Ryan; Fergus P McCarthy; Alun Hughes; Chloe Park; Abigail Fraser; Laura D Howe; Patricia M Kearney; Linda M O'Keeffe Journal: BMC Med Date: 2021-03-25 Impact factor: 8.775